---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-152426"
form_type: "8-K"
ticker: "TECX"
cik: "0001681087"
company_name: "Tectonic Therapeutic, Inc."
filed_at: "2022-05-17T23:59:59+00:00"
generated_at: "2026-06-25T12:13:53.579087+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AVROBIO reports positive Phase 1/2 gene therapy data for cystinosis; all 5 patients off oral cysteamine

## Summary
- All five dosed patients remain off oral cysteamine post gene therapy; no drug-related adverse events reported.
- Early data show stabilization/improvement in visual motor integration, perception, and motor coordination scores (Beery VMI).
- Cystine crystals reduced in skin (8-81%) and intestinal mucosa (28-83%) across patients 1-3 post gene therapy.
- Photophobia scores improved or stable; patients #1,3,4,5 off cysteamine eye drops.
- AVROBIO-sponsored trial planned to begin in 2023 after regulatory interactions.

## SEC filing metadata
- accession: 0001193125-22-152426
- form_type: 8-K
- ticker: TECX
- cik: 0001681087
- company_name: Tectonic Therapeutic, Inc.
- filed_at: 2022-05-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681087/000119312522152426/0001193125-22-152426-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681087/000119312522152426/d312223d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-152426
- JSON: https://secwatch.observer/filing/0001193125-22-152426.json
- Plain text: https://secwatch.observer/filing/0001193125-22-152426.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.